East Journal of Nursing (ME-JN) complies with the Recommendations
for the Conduct, Reporting, Editing, and Publication of Scholarly
Work in Medical Journals, issued by the International Committee
of Medical Journal Editors (ICMJE Recommendations), and
to the Committee on Publication Ethics (COPE) code of conduct
for editors guidelines:
Recommendations for the Conduct, Reporting, Editing, and
Publication of Scholarly Work in Medical Journals
1. Statements, permissions, and signatures
o Designated authors should meet all four criteria for authorship
in the ICMJE Recommendations
o We ask all authors, and all contributors (including medical
writers and editors), to specify their individual contributions
at the end of the text
o ME-JN will not publish any articles unless we have the signatures
of all authors
o We suggest you use the author statement form (below) and
upload or fax the signed copy with your submission
o In addition, please include written consent of any cited
individual(s) noted in acknowledgments or personal communications
A conflict of interest exists when professional judgement
concerning a primary interest (such as patients' welfare or
validity of research) may be influenced by a secondary interest
(such as financial gain).
are easily identifiable, but conflicts can also occur because
of personal relationships or rivalries, academic competition,
or intellectual beliefs. A conflict can be actual or potential,
and full disclosure to the Editor is the safest course. Failure
to disclose conflicts might lead to publication of a statement
in our Department of Error or even to retraction. All submissions
must include disclosure of all relationships that could be
viewed as presenting a potential or actual conflict of interest.
may use such information as a basis for editorial decisions,
and will publish such disclosures if they are believed to
be important to readers in judging the manuscript. Agreements
between authors and study sponsors that interfere with authors'
access to all of a study's data, or that interfere with their
ability to analyse and interpret the data and to prepare and
publish manuscripts independently, may represent conflicts
of interest, and should be avoided.
o At the end
of the text, under a subheading "Conflicts of interest",
all authors must disclose any financial and personal relationships
with other people or organisations that could inappropriately
influence (bias) their work. Examples of financial conflicts
include employment, consultancies, stock ownership, honoraria,
paid expert testimony, patents or patent applications, and
travel grants, all within 3 years of beginning the work submitted.
If there are no conflicts of interest, authors should state
o All authors
are required to provide a signed statement of their conflicts
of interest as part of the author statement form.
o For Comment, Seminars, Reviews, and Series, ME-JN will not
publish if an author, within the past 3 years, and with a
relevant company or competitor, has any stocks or shares,
equity, a contract of employment, or a named position on a
company board; or has been asked by any organisation other
than ME-JN to write, be named on, or to submit the paper.
of the funding source
o All sources of funding should be declared as an acknowledgment
at the end of the text
o At the end of the Methods section, under a subheading "Role
of the funding source", authors must describe the role
of the study sponsor(s), if any, in study design; in the collection,
analysis, and interpretation of data; in the writing of the
report; and in the decision to submit the paper for publication
o If there is no Methods section, the role of the funding
source should be stated as an acknowledgment. If the funding
source had no such involvement, the authors should so state
o The corresponding author should confirm that he or she had
full access to all the data in the study and had final responsibility
for the decision to submit for publication.
of medical writer or editor
o If a medical writer or editor was involved in the creation
of your manuscript, we need a signed statement from the corresponding
author to include their name and information about funding
of this person
o This information should be added to the Acknowledgments
and/or Contributors section
o We require signed statements from any medical writers or
editors declaring that they have given permission to be named
as an author, as a contributor, or in the Acknowledgments
and other consents
o Appropriate written consents, permissions, and releases
must be obtained where you wish to include any case details,
personal information, and/or images of patients or other individuals
in ME-JN in order to comply with all applicable laws and regulations
concerning privacy and/or security of personal information.
Studies on patients or volunteers need approval from an ethics
committee and informed consent from participants. These should
be documented in your paper.
o Since the consent form needs to comply with the relevant
legal requirements of your particular jurisdiction, we do
not provide sample forms; this is your responsibility. Your
affiliated institution should be able to provide an appropriate
o For the purposes of publishing in ME-JN, a consent, permission,
or release should include, without limitation, publication
in all formats (including print, electronic, and websites),
in sublicensed and reprinted versions (including translations),
and in other works and products.
o To respect your patient's and any other individual's privacy,
please do not send signed forms to ME-JN. Please instead complete
the patient consent section of the Author statements while
retaining copies of the signed forms in the event they should
o If consent, permission, or release is made subject to any
conditions, ME-JN must be made aware in writing of all such
conditions before publication.
o For more information please visit http://www.me-jn.com/authorinfo.htm
All manuscripts must be accompanied by necessary statements.
Each author must read and sign all statements:
1. Authorship statement on criteria and responsibility.
2. Financial disclosure statement.
3. Copyright transfer statement (or the statement of federal
employment, if applicable).
4. Human and animal subject protections.
In addition, the corresponding author must sign:
5. Acknowledgment statement. If necessary, photocopy this
document to distribute to co-authors for their signatures.
Please send all copies to the Editorial Office at the time
you submit your manuscript.
For more information please visit http://www.me-jn.com/authorinfo.htm
At the external peer review stage you will need to send signed
copies of the following statements:
o Authors' contributions
o Conflicts of interest statements
o Statements of role, if any, of medical writer or editor
o Acknowledgments-written consent of cited individual
o Personal communications - written consent of cited individual
o Use of copyright-protected material-signed permission statements
from author and publisher
These statements can be scanned and submitted electronically.
To minimise delays, we strongly
advise that you prepare signed copies of these statements
before you submit your manuscript.
of article and manuscript requirements
Please ensure that anything you submit to MEJIM follows the
guidelines provided for each article type. For instruction
on how to format the text of your paper, including tables,
figures, panels, and references, please see
Author Info section.
o ME-JN prioritises reports of original research that are
likely to change clinical practice or thinking about a disease.
o We invite submission of all clinical trials, whether phase
1, 2, 3, or 4. For phase 1 trials, we especially encourage
those of a novel substance for a novel indication, if there
is a strong or unexpected beneficial or adverse response,
or a novel mechanism of action
o We encourage researchers to enrol women and ethnic groups
into clinical trials of all phases, and to plan to analyse
data by gender and by race
o Systematic reviews of randomised trials about diseases that
have a major effect on human health also might warrant rapid
peer review and publication
o Global public-health and health-policy research are other
areas of interest to ME-JN
o We require the registration of all interventional trials,
whether early or late phase, in a primary register that participates
in WHO's International Clinical Trial Registry Platform. (http://www.who.int/ictrp/network/trds/en/index.html)
We also encourage full public disclosure of the minimum 20-item
trial registration dataset at the time of registration and
before recruitment of the first participant. The registry
must be independent of for-profit interest
o Reports of randomised trials must conform to CONSORT 2010
and should be submitted with their protocols
o All reports of randomised trials should include a section
entitled Randomisation and masking, within the Methods section
o Cluster-randomised trials must be reported according to
CONSORT extended guidelines (http://www.consort-statement.org/extensions/extensions/)
o Randomised trials that report harms must be described according
to extended CONSORT guidelines
o Studies of diagnostic accuracy must be reported according
to STARD (http://www.stard-statement.org/)
o Observational studies (cohort, case-control, or cross-sectional
designs) must be reported according to the STROBE statement,
and should be submitted with their protocols
o We encourage the registration of all observational studies
on a WHO-compliant registry o Genetic association studies
must be reported according to STREGA guidelines (http://www.med.uottawa.ca/public-health-genomics/web/eng/strega.html)
o Systematic reviews and meta-analyses must be reported according
to PRISMA guidelines (http://www.prisma-statement.org/).
o To find reporting guidelines see:
should, as relevant:
o Be up to 3000 words with 30 references (the word count is
for the manuscript text only)
o Include an abstract (semistructured summary), with five
paragraphs (Background, Methods, Findings, Interpretation,
and Funding), not exceeding 300 words.
o For randomised trials, the abstract should adhere to CONSORT
o For intervention studies, the abstract should include the
primary outcome expressed as the difference between groups
with a confidence interval on that difference (absolute differences
are more useful than relative ones). Important secondary outcomes
can be included as long as they are clearly marked as secondary
o Use the SI system of units and the recommended international
non-proprietary name (rINN) for drug names. Ensure that the
dose, route, and frequency of administration of any drug you
mention are correct.
o Use gene names approved by the Human Gene Organisation (http://www.genenames.org/).
Novel gene sequences should be deposited in a public database
(GenBank, EMBL, or DDBJ), and the accession number provided.
microarray papers should include in their submission the information
recommended by the MIAME guidelines (http://www.mged.org/Workgroups/MIAME/miame.html).
Authors should also submit their experimental details to one
of the publicly available databases: ArrayExpress or GEO (http://www.ncbi.nlm.nih.gov/geo/)
o All accepted Articles should include a link to the full
study protocol published on the authors' institutional website
research into context
o The Discussion section should contain a full description
and discussion of the context. Authors are also invited to
either report their own, up-to-date systematic review or cite
a recent systematic review of other trials, putting their
trial into context of the review.
o We will consider clear and interesting Clinical Pictures
and videos submitted with a descriptive paragraph
o Authors must obtain signed informed consent from the patient
if included in visual material (see Patient consent)
This section should include a description of how authors searched
for all the evidence. Authors should also say how they assessed
the quality of that evidence - ie, how they selected and how
they combined the evidence.
Authors should state here what their study adds to the totality
of evidence when their study is added to previous work.
o Authors must obtain signed informed consent from the patient
(see Patient and other consents)
if you have any questions regarding our code of ethics contact:
Lesley Pocock, Ethics Editor,
Following is a summary of the
Ethics requirements for ME-JN - for full detail and implications
for your submissions also see Author Info.
1. Publication and authorship:
- list of references, financial support;
- no plagiarism, no fraudulent data;
- forbidden to publish same research in more than one journal.
2. Author's responsibilities:
- authors obliged to participate in peer review process;
- all authors have significantly contributed to the research;
- statement that all data in article are real and authentic;
- all authors are obliged to provide retractions or corrections
3. Peer review / responsibility for the reviewers:
- Judgments should be objective;
- reviewers should have no conflict of interest with respect
to the research, the authors and/or the research funders;
- reviewers should point out relevant published work which
is not yet cited;
- reviewed articles should be treated confidentially.
4. Editorial responsibilities:
- e.g. editors have complete responsibility and authority
to reject/accept an article;
- editors should have no conflict of interest with respect
to articles they reject/accept;
- only accept a paper when reasonably certain;
- when errors are found, promote publication of correction
- preserve anonymity of reviewers.
5. Publishing ethics issues
- Monitoring/safeguarding publishing ethics by editorial board;
- Guidelines for retracting articles;
- Maintain the integrity of the academic record;
- Preclude business needs from compromising intellectual and
- Always be willing to publish corrections, clarifications,
retractions and apologies when needed.
- no plagiarism, no fraudulent data.